Recent data suggest that tumor cells contaminating reinfused bone marrow may contribute t o relapse in patients undergoing autologous bone marrow transplantation. Purging strategies that are able t o remove these contaminating tumor cells need t o be developed. This study describes how electroporation (EP) can be used t o improve intracellular delivery of synthetic antisense oligodeoxynucleotides (ODNs), thereby enhancing their ability to suppress a target protein.
Recent data suggest that tumor cells contaminating reinfused bone marrow may contribute t o relapse in patients undergoing autologous bone marrow transplantation. Purging strategies that are able t o remove these contaminating tumor cells need t o be developed. This study describes how electroporation (EP) can be used t o improve intracellular delivery of synthetic antisense oligodeoxynucleotides (ODNs), thereby enhancing their ability to suppress a target protein.
Antisense ODNs that were introduced into cells by EP led t o immediate suppression of targeted c-myc protein; this was associated with rapid cell death in the diffuse histiocytic lymphoma, U937; Burkitt's lymphoma, ST486; breast carcinoma, MCF-7; and Ewing's sarcoma, CHP-100, cell lines. Electroporation was found t o have little or no detrimental effect on cells responsible for murine hematopoietic long-term re-
UTOLOGOUS bone marrow transplantation (ABMT) is
A an effective means of providing hematopoietic rescue for patients who receive lethal, myeloablative doses of chem~radiotherapy.'.~ One potential limitation to ABMT is the possibility of tumor relapse originating from malignant cells contaminating the marrow. Recent gene marking studies have confirmed the ability of reinfused malignant cells to contribute to relapse after ABMT in patients with acute or chronic myelogenous le~kemia'~ and in patients with neuroblastoma.' Such findings suggest that efforts need to be directed towards the efficient removal of tumor cells from harvested marrow for at least these three, and perhaps other, malignancies treated by ABMT.
To be useful, purging techniques must effectively remove, destroy, or disable malignant cells while sparing cells responsible for hematopoietic reconstitution. Attempts at purging have used a variety of approaches: chemotherapeutic agents,x-" immunologic and cytokine selection techniques," and antisense-based purging strategies. I 3 Antisense oligodeoxynucleotides (ODNs) are pharmaceutical agents that are directed towards complementary target regions of mRNA; once bound, they can, at least theoretically, inhibit the synthesis of a single protein.l4-I6 The ability to target a single gene product may be particularly important in malignancies that contain unique chromosomal trans location^."^'^ For malignancies that do not contain a unique translocation, relative specificity may be achieved by targeting proteins that play an important role in that particular malignancy.'*-*"
Achieving adequate intracellular incorporation of ODNs is one limitation to an antisense-based purging approaCh,~4.1~,~~ We have previously shown that ODN delivery and efficacy can be improved through the use of electroporation.'"'' Electroporation (EP) involves briefly exposing cells to an electric field, which leads to the transient formation of pores in the plasma membrane through which ODNs may directly enter the cell.** By using EP to introduce antisense ODNs into the U937 human lymphoma cell line, 100% transfection rates were attainable and rapid, specific suppression of c-myc protein was achieved; rapid c-myc suppression was associated with decreased cell viability." constitution as determined from in vivo competitive repopulation studies. Using human c-myc-directed antisense ODNs as a model for the application of this approach t o bone marrow purging, selective killing of human lymphoma U937 cells relative t o normal human bone marrow cells was shown in cell mixing studies. In vivo studies were performed in which a survival advantage was shown for athymic mice that were inoculated with antisense-treated U937 cells as opposed t o control cells. These studies suggest that EP of bone marrow may be of use in enhancing intracellular delivery of a variety of molacularlpharmaceutical agents. Taken together, these data suggest that the use of electroporation t o enhance delivery of antisense ODNs is a promising new approach towards ex vivo bone marrow purging. Although this approach appears promising for ex vivo BM purging, the effects EP and of c-myc antisense on normal BM need to be characterized before considering the use of this approach in a clinical setting. Prior studies by various investigator^'^-*^ have shown that EP had no significant effect on committed BM progenitor cells. In the current study, those findings were confirmed and extended through the use of a murine competitive repopulation assay in which the long-term repopulation capability of electroporated murine BM cells was measured. In separate studies, using human cmyc -directed antisense ODNs, selective purging of human lymphoma cells from normal human BM was shown. When this approach was applied to an animal xenograft model, a survival advantage was shown for animals receiving malignant cells in which c-myc antisense was introduced by EP.
Collectively, these results suggest that the use of EP to introduce ODNs into cells in the ABMT setting is an approach that may selectively kill neoplastic cells while sparing normal BM function.
mented with 10% heat-inactivated fetal bovine serum (FBS; BioWhittaker, Walkersville, MD). ST486 cells were maintained in RPMI 1640, 15% FBS, and 300 mg/mL glutamine. MCF-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Biofluids, Rockville, MD), 10% FBS, and 300 mg/mL glutamine. All cells were maintained at 3 7 T , 6% carbon dioxide, except ST486 cells, which were maintained in air-tight flasks to increase carbon dioxide content. Media were changed twice weekly for all cell types. During cell viability studies, cells were cultured in the continued presence of oligodeoxynucleotide after electroporation. At the specified time periods, cell viability was assessed by determining the ability to exclude trypan-blue.
ODN synrhesis. ODNs were synthesized as reported previously." The c-myc antisense ODN (myc-AS) is an oligomer of 15 bases and is directed towards the initiation codon region of the c-myc mRNA. Fluorescein-labeled myc-AS (myc-FITC) ODN is an oligomer of 16 bases and was synthesized by adding an internal fluorescein-phosphoramidite base to myc-AS, as described previously.'' The scrambled ODN (myc-SCR) contained the same base composition as myc-AS, although bases were in scrambled order. All ODNs contained phosphorothioate linkages between each base. ODNs were purified as described and sterilized by filtration through a 0.22-pm filter. Before use, samples were checked for purity by polyacrylamide gel electrophoresis.
EP was performed as previously described.'" Briefly, 1 to 5 X IO6 U937, MCF-7, CHP-100, or ST486 cells; 2 X IO' low-density normal human BM cells; or the BM from two mice were suspended in I mL of media, placed into 0.4-cm gap EP chambers, and electroporated with a Cell-Porator Electroporation System 1 (GIBCO-BRL). U937, MCF-7, ST486, murine BM, and normal human BM cells were suspended in DMEM and electroporated at 1,180 pF, 260 V, at room temperature; FBS was then added to 10%. CHP-100 cells were electroporated in RPMI 1640 and supplemented with 10% FBS at 300 V, 1,180 pF. ODNs were added to the cell suspension just before EP; the final concentration of myc-AS and myc-SCR ODNs was 50 pmol/L, whereas for the myc-FITC ODN, the final concentration was 25 pmol/L.
Western analysis of c-myc protein. Levels of c-myc protein were assessed 1.5 hours after EP in all cells except ST486, in which cmyc protein was measured 18 hours after EP. Three to five million cells were washed with phosphate-buffered saline and lysed, and cmyc protein levels were determined as previously reported.'' So that changes in c-myc protein levels could be interpreted in relation to that of all cellular proteins, all lanes of a particular cell line were normalized for total cellular protein levels in the Western blot.
Cellular ODN pharmacokinetic studies. Twenty-five micromoles per liter of myc-FITC was added to U937 cells at time 0. After EP, cells were maintained in the presence of myc-FITC for 12 hours (the uptake period). Control cells were not electroporated but were maintained in the presence of myc-FITC for 12 hours. After 12 hours, cells were washed once in RPMI 1640, supplemented with 10% FBS, and maintained for up to 72 hours in myc-FITCfree media (the washout period). At various times after EP, cellassociated fluorescence was determined using flow cytometry. Propidium iodide was used to exclude nonviable cells. At the corresponding time points, cytospin preparations were made and used for fluorescence photomicroscopy.
After EP, U937 cells were cultured in the continued presence of ODN for 12 hours. Cells were then washed once in DMEM, suspended in 100 pL of DMEM, and implanted subcutaneously into the flank of 4-to 8-week-old female athymic mice (Frederick Cancer Research Facility, Frederick, MD). Each mouse was implanted with lo6 viable (trypan-blue excluding) cells, thus receiving an equal tumor burden. All mice were
Electroporation.
Human tumor cell xenograji experiments. maintained in a sterile, specific pathogen-free environment and examined daily.
5-Fluorouracil (5-FU)-treated BM spleen colony-forming ussay.\. Spleen colony-forming assays (colony-forming unit-spleen [CFU-SI) were performed as previously described.zh~27 Briefly, 4 days before harvesting marrow, 12-to 18-week-old female (C57BL/6NCR) FI mice (Frederick Cancer Research Facility) received 150 mgkg of 5-FU (Hoffman-La Roche Inc, Nutley, NJ) by intraperitoneal injection. BM from femurs and tibias was harvested, washed twice in DMEM, exposed to hypotonic NH4CI to lyse erythrocytes, washed twice in DMEM, and suspended in DMEM. After EP, BM cells were placed into tissue culture flasks, diluted 1:lO with DMEM containing 10% FBS, and maintained at 37°C with 5% carbon dioxide. Twelve hours later, 2.5 to 5.0 X IO4 viable BM cells were injected via the tail vein into lethally irradiated mice ( I ,000 rad at 1 10 radmin from a Cesium-137 gamma ray source). Twelve days later, spleens were removed and placed into Telle's fixative (64% ethanol, 1.7% formalin, and 4.5% acetic acid) and macroscopic colonies were counted. All mice were maintained in a sterile, specific pathogen-free environment CFU-granulocvte-macrophage (CFU-GM) assuys ojnormal human donor BM cells. Low-density mononuclear BM cells were prepared as described.2H Briefly, BM cells were obtained from the iliac crest of normal donors after informed consent under a clinical protocol approved by the National Cancer Institute. Cells with a density of 5 1.077 g/mL were collected and washed three times with Hanks' balanced salt solution after separation on a Ficoll-sodium diatrizoate gradient (LSM; Organon Teknika Corp, Durham, NC). Cells were then diluted to 2 X IOh cells/mL in an enriched Iscove's modified Dulbecco's medium containing 10% heat-inactivated FBS (Hyclone, Logan, UT) and incubated in tissue culture flasks 2 hours at 37°C with 5% carbon dioxide. Nonadherent cells were collected and used for CFU-GM assays. Twelve hours after EP (control cells were not electroporated), cells were washed twice in DMEM and suspended in methylcellulose containing 5% phytohemagglutinin lymphocyte conditioned media (PHA-LCM; Stem Cell Technologieb, Vancouver, British Columbia, Canada) to stimulate colony growth as described." One-milliliter aliquots containing 5 X IO4 low-density BM cells were plated into 35-mm tissue culture dishes (Nunc, Naperville, IL) and maintained under humidified conditions at 3 7 T , 5% carbon dioxide. After 14 days, colonies containing 2 5 0 cells were counted as derived from CFU-GM.
Separate studies in our laboratory have shown that, when normal human BM cells and human malignant lymphoma U937 cells were premixed before placement in electroporation chambers, a selective removal of viable U937 cells occurred in control samples (unpublished observations). Therefore, to ensure the presence of U937 cells in normal BM, U937 cells and normal human donor low-density BM cells were each separately subjected to EP and exposed to c-myc antisense ODN in an identical manner, as indicated. After incubating for 12 hours in their respective conditions. U937 cells and normal BM cells, which had been treated in an identical manner, were mixed together in DMEM without ODN before culturing. The final ratio of U937 cells to BM cells was either 1:lOO or 1:50 (1% to 2%). Cell mixtures were then cultured in either methylcellulose containing 5% PHA-LCM for CFU-GM colony formation or were cultured in RPMI 1640 containing 10% FBS for U937 cell viability. CFU-GM and U937 colonies in methylcellulose could easily be discriminated (Fig 1) and, after 14 days, were counted. No colonies identified as U937 turned out to be CFU-GM colonies and less than 0.75% of those identified as CFU-GM colonies turned out to be U937 colonies as determined by ability to sustain continued growth when transferred to unsupplemented media, continued observation of characteristic growth pattern in methylcellulose, and
Mixing assays.
For personal use only. on October 27, 2017. by guest www.bloodjournal.org comparison to colony identification when U937 and BM cells were separately cultured in methylcellulose (unpublished observations). For U937 cell viability studies, single-cell dilutions were made of U937 cells into microtiter plates and cell growth assessed 28 days after plating. Under these conditions, 25% to 50% of U937 cells were capable of sustained cell growth by 28 days as determined by the presence of multiple viable U937 cells in a well to which a single U937 cell had been placed. There was no cell growth of low-density BM cells plated under these conditions even after up to 500 cells per well had been seeded. Single-cell U937 colony-forming capability was only 6% when cells were cultured in methylcellulose containing 5% PHA-LCM (ie, CFU-GM assay conditions).
Hematopoietic stem cell activity was assayed by performing competitive repopulation assays as described by Harrison et al.'" Briefly, 8-week-old C57BW6-Ly5.2 (B6-Ly5.2) mice were used as donors of BM undergoing EP or sham EP treatment. Female C57BL/6-Ly5.1 (B6-Ly5.1) mice, aged 8 and 14 weeks, respectively, were used Hemaiopoieiic repopulating cell assay.
as donors of competitive (untreated) marrow and as transplant hosts. BM was collected from femurs and tibias of B6-Ly5.2 mice that were pretreated 4 days before with 150 mglkg body weight of 5-FU intraperitoneally. The marrow was then washed in Hanks' balanced salt solution (GIBCO) and subjected to EP or sham EP. The following day, marrow from untreated B6-Ly5.1 mice was collected and a mixture of EP or sham EP B6-Ly5.2 marrow cells and untreated B6-Ly5. I marrow was injected intravenously via the tail vein into lethally irradiated (1,000 rad at I10 radlmin from a Cesium-I37 gamma ray source) B6-Ly5.1 hosts. After 16 to 18 weeks, blood from the tail veins of host mice was collected into heparized tubes, erythrocytes were lysed, and leukocytes were stained with anti-Ly5.2 (A20-1. Inc, Cupertino, CA). Gates were set on FSC/FL-3 to exclude dead cells based on propidium iodide (Sigma, St Louis, MO) exclusion: 10.000 events were acquired for each analysis. Chimerism in CD45' (Ly5') populations was identified using FL-IISSC.
RESULTS
c-myc protein levels decrease rapidlv afer electroporation. Several cell lines (diffuse lymphoma, U937; breast carcinoma, MCF-7; Ewing's sarcoma, CHP-100; and Burkitt's lymphoma, ST486) representative of neoplasms with known BM involvement were electroporated in the presence of myc-AS or myc-SCR ODNs. Expression of c-myc protein was then evaluated by Western blot 1.5 hours after EP ( 1 8 hours in the case of the ST486 cell line). As shown in Fig  2, there was a specific decrease in c-myc protein in all four of the cell lines tested after treatment with myc-AS; however, there was some degree of c-myc suppression by myc-SCR. There was no evidence of c-myc protein suppression when cells were incubated for up to 24 hours in the presence of myc-AS without EP'7.'9." (Bergan et al, unpublished data).
Cell viabiliry of neoplastic cell lines after EP in the presence of myc-AS. The viability of various cell lines was assessed 18 hours (48 hours for MCF-7 cells) after EP in the presence and absence of ODN. As shown in Table I , EP alone did not affect cell viability in the CHP-100 cell line, whereas the viability of other cell lines was decreased to as low as 65%. Compared with EP alone, the combination of EP and myc-AS decreased viability in all four cell lines tested (P < .006 in all cases). The effect of EP plus myc-AS was most pronounced in the MCF-7 breast carcinoma BERGAN ET AL cell line (cell viability was 25% of non-EP cells) and least pronounced in the ST486 Burkitt's lymphoma cell line (cell viability was 56% of non-EP cells). Toxic effects by myc-SCR were seen in the MCF-7 and CHP-100 cell lines. However, in all cases, treatment with myc-AS killed more cells than myc-SCR ( P < .026).
To evaluate the effect of EP on ODN intracellular distribution, myc-FITC was added to U937 cells that were subsequently electroporated (EP+); control cells were maintained without EP (EP-). Cell-associated fluorescence was determined at various times after the addition of myc-FITC (Fig 3A) . Throughout the 72-hour study period, more ODN was detected in EP+ cells than in the EP-cells. Because of transient fragility induced by EP, it was not possible to perform flow cytometric analysis at time points earlier than 1 hour. There was almost a sevenfold increase in mean cell fluorescence intensity at the I-hour time point in EP+ cells as compared with EP-cells (Fig 3B) . During the first 12 hours (while cells were still exposed to ODN), there was continued cellular uptake in both EP+ and EP-groups. Once exogenous ODN was removed, the cellular fluorescence of each group and the EP+/EP-fluorescence ratio decreased slowly over ti me.
Comparison of EP+ and EP-fluorescence micrographs (Fig 4) shows a marked difference in intracellular myc-FITC distribution. In EP-cells, ODN remains confined primarily to vesicular cytoplasmic structures, sparing the nucleus. However, in EP+ cells, ODN localizes to the nucleus and to extravesicular cytoplasmic structures. These differences in subcellular distribution can still be detected at 72 hours.
The findings mentioned above suggested that EP may be useful for improving the delivery of ODNs as part of an ex vivo BM purging strategy. A series of studies were therefore performed to determine the effect of EP on normal hematopoiesis. BM from 5-FUtreated mice has been shown to be enriched for relatively primitive progenitor cells and stem cell^.'"^^^^'^ The effect of EP upon such an enriched population of primitive hematopoietic progenitors was evaluated by assaying CFU-S colony-forming capability of BM from 5-FU-treated mice. Table 2 shows the resultant number of day-I2 CFU-S-derived colonies from marrow that was subjected to EP as compared with that of control marrow that was not subjected to EP. At the .05 level of significance, there was no difference between the number of CFU-S-derived colonies in control and EP groups. When normalized for percentage of donor marrow injected, there was a trend towards a decreased number of CFU-S-derived colonies per donor in the group of mice injected with 2.5 x IO4 viable cells; however, this decrease was not statistically significant at the .05 level of significance. Thus, as determined by CFU-S colony formation, EP had no or little effect on murine progenitor cell numbers.
The effect of EP on murine hematopoietic repopulating cells was then determined by performing a competitive repopulation study using donor mice expressing an allelic form of the leukocyte common antigen CD45 (Ly5.2 v Ly5.1). In such an assay, the functional capacity of one stem cell population (Ly5.2 cells in our system) is measured by comparing it to the function of another stem cell population (ie, host Ly5.1 stem cells). The two stem cell populations are allelic variants and are functionally syngeneic in host animals and therefore both can contribute to (compete for) BM repopulation.
BM was collected from 5-FW-treated B6-Ly5.2 donor mice and subjected to EP or sham EP (control). Control or EP-treated Ly5.2 cells were then mixed with normal B6 (Ly5.1) host marrow and transplanted into irradiated B6 hosts. After 4 months, chimerism was assessed by flow cytometry (Table 3) . Because of the sensitivity of the assay, it was possible to detect CD45 (Ly5) chimerism as low as 1.5% in mice receiving as few as 3 X 10" B6-Ly5.2 marrow cells. The ability of non-EP (control) donor Ly5.2 cells to compete with host cells for BM repopulation was first determined by using the technique of Harrison et a130 to calculate repopulation units in the original donor inocula. This gave a baseline measure of Ly5.2 stem cell function (defined in relation to host stem cell function) of 3.79 2 0.54 (mean ? SE; n = 3) repopulation units per lo5 donor (Ly5.2) cells. Next, the ability of EP Ly5.2 cells to compete with host cells was determined, thus giving a measure of EP Ly5.2 donor stem cell function of 3.05 ? 0.5 (mean ? SE; n = 3) repopulation units per lo5 donor (Ly5.2) cells. In these studies, no significant difference in long-term chimerism was observed between mice receiving EP and sham EP B6-Ly5.2 marrow cells (P = .42; Student's t-test).
Introduction of c-myc antisense ODNs into cells by EP selectively purges malignant human lymphoma cells. To determine if the introduction of myc-AS by EP will selectively kill U937 human lymphoma cells relative to normal human BM, a mixing study was performed. In this study, U937 cells and normal human BM low-density cells were each subjected to EP and exposure to c-myc antisense, as indicated. After incubating for 12 hours in their respective treatment conditions, cells were placed into ODN-free media. U937 cells and normal BM cells, which were treated in an identical manner, were then mixed together. This mixture was then assayed for CFU-GM colony formation and singlecell U937 clonagenic activity. By conducting the mixing assays in this fashion, it was possible to avoid the spurious decrease in U937 cell numbers that occurs in control samples when U937 cells and normal BM cells are premixed. This approach also allowed all cells to be treated in an identical fashion, except for the indicated experimental variables, while ensuring the presence of malignant U937 cells in normal BM. Figure 5 depicts the results from a typical experiment in which 14-day CFU-GM colony formation and 28-day U937 single-cell clonagenic activity was measured using normal human donor low-density BM cells that were contaminated (1%) with malignant human lymphoma U937 cells. There was no significant decrement in CFW-GM colony formation when EP was used to introduce myc-AS (P 2 .22, n = 4).
However, there was an 87% 2 2.0% (mean 2 SE, P 5 .001, n = 4) decrease in U937 cell viability when myc-AS was introduced by EP. It is of note that there was no significant decrease in U937 cell viability when cells were exposed to myc-AS without EP. Except for a selective depletion of U937 cells in control samples when cells were premixed, identical results were obtained when cells were premixed as compared to those when cells were mixed after manipulation (unpublished observations).
To determine if these in vitro cell killing effects can be seen in vivo, the growth of U937 cells in a murine xenograft model was assessed. U937 cells were subjected to EP in the presence and absence of myc-AS and subsequently implanted subcutaneously into athymic mice. When as few as 0.5 X lo6 non-EP U937 cells were implanted subcutaneously, there was 110% survival at 6 weeks; there was no significant difference in tumor growth between non-EP cells and cells that were exposed to myc-AS without EP (data not shown). The survival curve in Fig 6 therefore By increasing cellular uptake, decreasing exposure time, and providing a more advantageous subcellular distribution survival of mice that received IO6 viable U937 cells that were electroporated in the presence of myc-AS with that of those that received lo6 viable U937 cells that were EP in the absence of myc-AS. Because each mouse received an equal number of viable cells and therefore received an equal tumor burden, any observed differences represent the effects of myc-AS that was electroporated into cells. Eighty-six percent of the myc-AS mice survived longer than 90 days, whereas only 24% of control mice survived 90 days ( P < .0001). At the conclusion of the experiment, all surviving mice had no gross evidence of tumor and appeared otherwise healthy.
DISCUSSION
Tumor cells contaminating autologous marrow may serve as a source of relapse after ABMT.5-7 To eliminate contami-
subcellular distribution is achieved instantaneously and is maintained for at least 3 days after EP. Consistent with previously reported findings in other cell types," electroporated U937 cells had a sevenfold increase in the level of intracellular ODN as compared with control cells, with ODN transfection rates of 100% (unpublished observations). Cells were exposed to exogenous ODN for 12 hours in this study; during this time period, cellular ODN uptake was occurring through endocytosis. However, even after 12 hours, nuclear-based ODN (ie, ODN taken up during EP) still predominated within EP cells. The length of an ODN, at least for ODNs that are between 15 and 28 bases, does not significantly affect ednocytotic uptake into the Likewise, ODN length does not appear to affect EP-mediated ODN delivery, at least for ODNs ranging in size from 15 to 21 base^.".^^,^' EP is a physical process that has been applied to a wide variety of cell and tissue EP-mediated ODN delivery will likely be applicable to a variety of primary human tumor types.
Improved intracellular ODN delivery was associated with rapid c-myc protein suppression, which was seen by 90 minutes in all cell lines tested except the Burkitt's lymphoma ST486 cell line, in which suppression was not evident until 18 hours. It is interesting to note that the ST486 cell line contains a translocation between chromosomes 14 and 8 that juxtaposes the c-myc gene and the Ig heavy chain promotor, resulting in constitutive overexpression of c-myc ~rotein.~' In other studies targeting c-myc protein, long ODN exposure times were typically required; these studies included the Burkitt's lymphoma, ST486I7; breast carcinoma, MCF-731; Ewing's sarcoma, CHP-10043; and human lymphoma, U937,ly cell lines used in the present study, as well as other cell lines.",45 Rapid ODN delivery and c-myc suppression was associated with cell death in all four cell lines tested.
EP-mediated ODN delivery appears particularly suited to the ex vivo purging of autologous BM before autografting. For personal use only. on October 27, 2017. by guest www.bloodjournal.org From To provide information for further investigations involving the use of EP-mediated drug delivery in murine preclinical transplant models, murine studies designed to measure the effects of EP on BM were performed. Antisense to c-myc was not tested in the murine studies because the murine cmyc antisense model has not been defined. However, studies with human cells were performed with the well-characterized human c-myc antisense system.
Using normal human donor BM or post-5-FU-treated murine BM (enriched for relatively primitive progenitor cells and stem cells), we have confirmed and extended the findings of Toneguzzo and Keati~~g'~.'~ and of Narayanan et al,25 who showed that EP had no significant effect on CFU-GM or CFU-S colony formation, respectively. The murine studies were extended by performing competitive repopulation assays; apart from human clinical studies, murine competitive repopulation assays represent the gold standard for the measurement of stem cell activity in vivo. Using this rigorous assay, EP was shown not to decrease the repopulating capacity of marrow from 5-FU-treated mice, and thus important information for further preclinical model development is provided.
In designing the human antisense studies, we chose to target c-myc protein because its deregulation has been linked to carcinogenesis at multiple steps and in many tumor types, suggesting a potential wide applicability of c-myc as a tarFurthermore, while the novel effects of EP were being investigated, it was desirable to use a well-defined antisense model; c-myc represents such a model. Antisensemediated targeting of c-myc has been successful in a variety For U937 cells, significant differences were seen between CO and EP-AS (P 5 .OOl) and between EP-AS and CO-AS (P 5 .003) treatments, whereas there was no significant difference between CO and CO-AS treatments (P 2 .052).
of systems"" and is a system with which our laboratory has extensive experience. 17."). 431s Using human c-myc-directed antisense in mixing studies involving normal human BM cells and human malignant lymphoma U937 cells, selective killing of neoplastic cells was achieved when ODNs were introduced by EP. The wellknown association of c-myc expression and cellular proliferation, especially as it pertains to malignant ce1k:"-4x presumably accounts for this selectivity. U937 cells exposed to ODN, but not EP, were not affected, thus showing the importance of EP in this system. It became apparent while performing the mixing studies that a selective removal of U937 cells from normal BM cells was occurring in control samples when U937 cells and normal BM cells were premixed. The reasons for this may relate to selective mechanical trapping of the larger and potentially more adherent U937 cells (a cell line with monocyte/macrophage characteristics) in the small gap between the electrode and the side of the electroporation chamber. Both electroporation22 and the addition of negatively charged ODNsJ9 are known to alter cell surface properties and would explain why this phenomenon is observed only in control samples. The decision to mix U937 cells and normal BM cells treated in an identical manner after manipulation represents a more rigorous approach in which the presence of malignant U937 cells in BM is ensured.
Although overall U937 cell kill was modest (87%) by conventional purging standards, selective killing was achieved. In the xenograft model, this translated into prolongation of survival, suggesting that these effects can be of benefit in an in vivo setting. The factors responsible for this are not clear at this time, but may relate to an increased dependence on c-myc in the in vivo setting. It is also possible that cell kill in the in vivo setting may involve other mechanisms (such as a bystander effect) in which antisense-mediated cell kill is the initiating event, but is, itself, directly responsible for only a certain percentage of cell kill. This is an important question and is the subject of ongoing studies.
The decrease in viability of U937 cells electroporated in the presence of c-myc antisense from 45% at 12 hours after EP to 13% after 28 days suggests that there may be both immediate and delayed toxic effects. Although continued suppression of c-myc protein for up to 24 hours after EP has been previously shown using c-myc antisense and U937 cells,"' more studies will need to be performed before a causal relationship between continued c-myc suppression and delayed cell death can be determined.
Relative c-myc protein suppression and cell kill in several cell lines by c-myc antisense was shown despite significant effects by the c-myc-scrambled ODN. Although the mechanism of ODN action remains to be elucidated and is beyond the scope of this study, previous work has shown that RNase H does not play an important role in mediating c-myc protein suppression in U937 cells:1 whereas other work has explored For personal use only. on October 27, 2017. by guest www.bloodjournal.org From
